Chengping Hu
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Oncology top 0.5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Treatments and Mutations 36
- Lung Cancer Diagnosis and Treatment 11
- Oncology 36
- Cancer Immunotherapy and Biomarkers 11
- Lung Cancer Research Studies 10
- Colorectal Cancer Treatments and Studies 7
- Co-authors
- Yi-Long Lung Cancer Wu (12 shared papers)Shun Lü (12 shared papers)Caicun Zhou (7 shared papers)Jifeng Feng (8 shared papers)Mei Hou (5 shared papers)Yunchao Huang (4 shared papers)Chong‐Rui Xu (3 shared papers)Dan Massey (3 shared papers)
- Journals
- Annals of Oncology (12 papers)PLoS ONE (6 papers)Journal of Thoracic Oncology (6 papers)Lung Cancer (4 papers)Translational Lung Cancer Research (4 papers)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Chengping Hu
191 papers receiving 11.4k citations
Chengping Hu's Hit Papers
Peers
Comparison fields: 5 of 139
- Pulmonary and Respiratory Medicine 6.3k
- Oncology 4.2k
- Cancer Research 1.7k
- Molecular Biology 2.7k
- Immunology 727
Countries citing papers authored by Chengping Hu
This map shows the geographic impact of Chengping Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengping Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengping Hu more than expected).
Fields of papers citing papers by Chengping Hu
This network shows the impact of papers produced by Chengping Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengping Hu. The network helps show where Chengping Hu may publish in the future.
Co-authors
The 25 scholars most cited alongside Chengping Hu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 193 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Hit paper breakdown → | 2011 | 3516 |
| 2 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial Hit paper breakdown → | 2014 | 1736 |
| 3 | Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) Hit paper breakdown → | 2015 | 401 |
| 4 | 2019 | 302 | |
| 5 | Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 285 |
| 6 | Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12) Hit paper breakdown → | 2021 | 247 |
| 7 | 2016 | 223 | |
| 8 | AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations Hit paper breakdown → | 2022 | 209 |
| 9 | 2016 | 159 | |
| 10 | 2017 | 155 | |
| 11 | 2018 | 142 | |
| 12 | 2017 | 141 | |
| 13 | 2016 | 124 | |
| 14 | 2013 | 117 | |
| 15 | 2020 | 109 | |
| 16 | 2013 | 104 | |
| 17 | 2019 | 101 | |
| 18 | Competing endogenous RNA in cancer: a new pattern of gene expression regulation. | 2015 | 99 |
| 19 | 2021 | 97 | |
| 20 | 2011 | 89 |
About Chengping Hu
Chengping Hu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Physiology and Immunology, having authored 193 papers that have together received 11.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (36 papers), Asthma and respiratory diseases (16 papers), Cancer Immunotherapy and Biomarkers (11 papers), Lung Cancer Diagnosis and Treatment (11 papers), Lung Cancer Research Studies (10 papers), MicroRNA in disease regulation (10 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cancer-related molecular mechanisms research (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (6.3k citations), Oncology (4.2k citations), Cancer Research (1.7k citations), Molecular Biology (2.7k citations) and Immunology (727 citations). Chengping Hu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Yi-Long Lung Cancer Wu, Shun Lü, Caicun Zhou, Jifeng Feng, Mei Hou, Yunchao Huang, Chong‐Rui Xu, Dan Massey, Sarayut Lucien Geater and Jian Hua Shi. Their work appears in journals such as Annals of Oncology, PLoS ONE, Journal of Thoracic Oncology, Lung Cancer and Translational Lung Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.